FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294976193> ?p ?o ?g. }

• W2294976193 endingPage "29973" @default.
• W2294976193 startingPage "29964" @default.
• W2294976193 abstract "Immune cells are believed to participate in initiating anti-tumor effects during regular tumor therapy such as chemotherapy, radiation, hyperthermia, and cytokine injection. One of the mechanisms underlying this process is the expression of so-called stress-inducible immunostimulating ligands. Although the activating receptor NKG2D has been proven to play roles in tumor therapy through targeting its ligands, the role of NKp30, another key activating receptor, is seldom addressed. In this study, we found that the NKp30 ligand B7-H6 was widely expressed in tumor cells and closely correlated to their susceptibility to NK cell lysis. Further studies showed that treatment of tumor cells with almost all standard tumor therapeutics, including chemotherapy (cisplatin, 5-fluorouracil), radiation therapy, non-lethal heat shock, and cytokine therapy (TNF-α), could up-regulate the expression of B7-H6 in tumor cells and enhance tumor sensitivity to NK cell cytolysis. B7-H6 shRNA treatment effectively dampened sensitization of tumor cells to NK-mediated lysis. Our study not only reveals the possibility that tumor therapeutics work as stress inducers to enhance tumor sensitivity to NK cell cytolysis but also suggests that B7-H6 could be a potential target for tumor therapy in the future. Immune cells are believed to participate in initiating anti-tumor effects during regular tumor therapy such as chemotherapy, radiation, hyperthermia, and cytokine injection. One of the mechanisms underlying this process is the expression of so-called stress-inducible immunostimulating ligands. Although the activating receptor NKG2D has been proven to play roles in tumor therapy through targeting its ligands, the role of NKp30, another key activating receptor, is seldom addressed. In this study, we found that the NKp30 ligand B7-H6 was widely expressed in tumor cells and closely correlated to their susceptibility to NK cell lysis. Further studies showed that treatment of tumor cells with almost all standard tumor therapeutics, including chemotherapy (cisplatin, 5-fluorouracil), radiation therapy, non-lethal heat shock, and cytokine therapy (TNF-α), could up-regulate the expression of B7-H6 in tumor cells and enhance tumor sensitivity to NK cell cytolysis. B7-H6 shRNA treatment effectively dampened sensitization of tumor cells to NK-mediated lysis. Our study not only reveals the possibility that tumor therapeutics work as stress inducers to enhance tumor sensitivity to NK cell cytolysis but also suggests that B7-H6 could be a potential target for tumor therapy in the future." @default.
• W2294976193 created "2016-06-24" @default.
• W2294976193 creator A5012198733 @default.
• W2294976193 creator A5032764121 @default.
• W2294976193 creator A5041353057 @default.
• W2294976193 creator A5043461142 @default.
• W2294976193 creator A5057081397 @default.
• W2294976193 creator A5083130438 @default.
• W2294976193 date "2015-12-01" @default.
• W2294976193 modified "2023-10-15" @default.
• W2294976193 title "Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6" @default.
• W2294976193 cites W1599718730 @default.
• W2294976193 cites W1642437933 @default.
• W2294976193 cites W1665466173 @default.
• W2294976193 cites W1969464492 @default.
• W2294976193 cites W1971514891 @default.
• W2294976193 cites W1977385137 @default.
• W2294976193 cites W1984341857 @default.
• W2294976193 cites W1996891899 @default.
• W2294976193 cites W1999020268 @default.
• W2294976193 cites W2002197941 @default.
• W2294976193 cites W2005804168 @default.
• W2294976193 cites W2023980114 @default.
• W2294976193 cites W2041953257 @default.
• W2294976193 cites W2047059912 @default.
• W2294976193 cites W2047902191 @default.
• W2294976193 cites W2056893124 @default.
• W2294976193 cites W2059354338 @default.
• W2294976193 cites W2060829712 @default.
• W2294976193 cites W2065985007 @default.
• W2294976193 cites W2067367325 @default.
• W2294976193 cites W2068568648 @default.
• W2294976193 cites W2071153515 @default.
• W2294976193 cites W2076329388 @default.
• W2294976193 cites W2080083059 @default.
• W2294976193 cites W2081816766 @default.
• W2294976193 cites W2083991703 @default.
• W2294976193 cites W2093424661 @default.
• W2294976193 cites W2101653483 @default.
• W2294976193 cites W2107854063 @default.
• W2294976193 cites W2108458140 @default.
• W2294976193 cites W2118401604 @default.
• W2294976193 cites W2123894372 @default.
• W2294976193 cites W2124755386 @default.
• W2294976193 cites W2144872368 @default.
• W2294976193 cites W2146313292 @default.
• W2294976193 cites W2154518608 @default.
• W2294976193 cites W2155056321 @default.
• W2294976193 cites W2159830797 @default.
• W2294976193 cites W2160834915 @default.
• W2294976193 doi "https://doi.org/10.1074/jbc.m115.674010" @default.
• W2294976193 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4705966" @default.
• W2294976193 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26472927" @default.
• W2294976193 hasPublicationYear "2015" @default.
• W2294976193 type Work @default.
• W2294976193 sameAs 2294976193 @default.
• W2294976193 citedByCount "63" @default.
• W2294976193 countsByYear W22949761932016 @default.
• W2294976193 countsByYear W22949761932017 @default.
• W2294976193 countsByYear W22949761932018 @default.
• W2294976193 countsByYear W22949761932019 @default.
• W2294976193 countsByYear W22949761932020 @default.
• W2294976193 countsByYear W22949761932021 @default.
• W2294976193 countsByYear W22949761932022 @default.
• W2294976193 countsByYear W22949761932023 @default.
• W2294976193 crossrefType "journal-article" @default.
• W2294976193 hasAuthorship W2294976193A5012198733 @default.
• W2294976193 hasAuthorship W2294976193A5032764121 @default.
• W2294976193 hasAuthorship W2294976193A5041353057 @default.
• W2294976193 hasAuthorship W2294976193A5043461142 @default.
• W2294976193 hasAuthorship W2294976193A5057081397 @default.
• W2294976193 hasAuthorship W2294976193A5083130438 @default.
• W2294976193 hasBestOaLocation W22949761931 @default.
• W2294976193 hasConcept C109316439 @default.
• W2294976193 hasConcept C17991360 @default.
• W2294976193 hasConcept C202751555 @default.
• W2294976193 hasConcept C203014093 @default.
• W2294976193 hasConcept C2777701055 @default.
• W2294976193 hasConcept C2778690821 @default.
• W2294976193 hasConcept C2778867473 @default.
• W2294976193 hasConcept C502942594 @default.
• W2294976193 hasConcept C55493867 @default.
• W2294976193 hasConcept C73588182 @default.
• W2294976193 hasConcept C86803240 @default.
• W2294976193 hasConcept C8891405 @default.
• W2294976193 hasConceptScore W2294976193C109316439 @default.
• W2294976193 hasConceptScore W2294976193C17991360 @default.
• W2294976193 hasConceptScore W2294976193C202751555 @default.
• W2294976193 hasConceptScore W2294976193C203014093 @default.
• W2294976193 hasConceptScore W2294976193C2777701055 @default.
• W2294976193 hasConceptScore W2294976193C2778690821 @default.
• W2294976193 hasConceptScore W2294976193C2778867473 @default.
• W2294976193 hasConceptScore W2294976193C502942594 @default.
• W2294976193 hasConceptScore W2294976193C55493867 @default.
• W2294976193 hasConceptScore W2294976193C73588182 @default.
• W2294976193 hasConceptScore W2294976193C86803240 @default.
• W2294976193 hasConceptScore W2294976193C8891405 @default.
• W2294976193 hasFunder F4320321001 @default.

• next